Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases
A Saxon, D Zhu, K Zhang, LC Allen… - Current Opinion in …, 2004 - journals.lww.com
Current Opinion in Allergy and Clinical Immunology, 2004•journals.lww.com
The balance between positive and negative signaling controls mast cell and basophil
reactivity, which is critical in the expression of human allergic diseases. This approach using
a human Fcγ-Fcε fusion protein to co-aggregate FcεRI with the FcγRII holds promise as a
new therapeutic platform for the immunomodulation of allergic diseases and potentially
other mast cell/basophil-dependent disease states.
reactivity, which is critical in the expression of human allergic diseases. This approach using
a human Fcγ-Fcε fusion protein to co-aggregate FcεRI with the FcγRII holds promise as a
new therapeutic platform for the immunomodulation of allergic diseases and potentially
other mast cell/basophil-dependent disease states.
Summary
The balance between positive and negative signaling controls mast cell and basophil reactivity, which is critical in the expression of human allergic diseases. This approach using a human Fcγ-Fcε fusion protein to co-aggregate FcεRI with the FcγRII holds promise as a new therapeutic platform for the immunomodulation of allergic diseases and potentially other mast cell/basophil-dependent disease states.
Lippincott Williams & Wilkins